Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00996515 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies
A Phase 1 study, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00996515 is a Phase 1 study that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 30 participants.
The verdict
NCT00996515, a Phase 1 study, has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
PRIMARY OBJECTIVES: I. To document the toxicities, and reversibility of toxicities, of this regimen of 5-azacytidine (azacitidine) and erlotinib (erlotinib hydrochloride). SECONDARY OBJECTIVES: I. To determine any potential anti-tumor effects, as determined by the objective tumor response (complete and partial responses), clinical benefit (complete and partial responses, and clinical benefit), the time to tumor response, the time to tumor progression, and the overall survival.
Interventions
- DRUG 5-azacytidine, erlotinib
- DRUG Erlotinib PO and Vidaza IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-06 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00996515
The ClinicalTrials.gov registry entry for NCT00996515 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 5-azacytidine, erlotinib is the first listed.
NCT00996515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00996515 about?
NCT00996515 is a clinical study titled "A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies". PRIMARY OBJECTIVES: I. To document the toxicities, and reversibility of toxicities, of this regimen of 5-azacytidine (azacitidine) and erlotinib (erlotinib hydrochloride). SECONDARY OBJECTIVES: I. To determine any potential anti-tumor effects, as determined by the objective tumor response (comple...
What is the current status of trial NCT00996515?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2008-06. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00996515?
The interventions under investigation include: 5-azacytidine, erlotinib (DRUG), Erlotinib PO and Vidaza IV (DRUG).
Who is sponsoring clinical trial NCT00996515?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.